SUPN (Supernus Pharmaceuticals) Short Interest


SUPN Supernus Pharmaceuticals Inc SUPN
87 GF Score
Price $45.13
GF Value $40.55
Valuation Modestly Overvalued
View Full Analysis

What is Supernus Pharmaceuticals Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

SUPN vs BCRX, PBH, ANIP: Short Interest Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Supernus Pharmaceuticals's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Supernus Pharmaceuticals Short Interest vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Supernus Pharmaceuticals's Short Interest distribution charts can be found below:

* The bar in red indicates where Supernus Pharmaceuticals's Short Interest falls into.


SUPN
87GF Score
Supernus Pharmaceuticals Inc SUPN
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Supernus Pharmaceuticals (SUPN) Overvalued in 2026?

Based on GuruFocus' analysis, Supernus Pharmaceuticals stock appears to be overvalued. The current stock price of $45.13 is trading 11.3% above its estimated GF Value™ of $40.55. GuruFocus considers Supernus Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for SUPN:

  • Short Interest:
  • GF Value™: $40.55 vs. price of $45.13 (11.3% above fair value)
  • GF Score™: 87/100

No single metric tells the full story. See the SUPN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Supernus Pharmaceuticals Business Description

Other Exchanges 0LB2:UKS49:Germany
Address 9715 Key West Avenue, Rockville, MD, USA, 20850
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
87GF Score

Get the complete analysis for SUPN

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$45.13
Price
$40.55
GF Value